PBS gatekeepers have signalled a willingness to be flexible on restrictions that currently prevent clinicians from prescribing the best treatments for multiple myeloma such as protease inhibitor (PI) and immunomodulatory drug (IMiD) dual therapy. In a meeting with stakeholders in May, the Pharmaceutical Benefits Advisory Committee (PBAC) said it understood the frustrations created by PBS ...
PBS offers flexibility on multiple myeloma drug listing restrictions
By Michael Woodhead
5 Sep 2018